Table 3.

Tumor characteristics of patients by molecular subtypes

	Luminal A	Luminal B		HER2‐enriched		Basal‐like
	n (%)	n (%)	OR (95% CI)	n (%)	OR (95% CI)	n (%)	OR (95% CI)
Calcification
No	1704 (36.0)	342 (26.7)	1.00 (ref)	371 (28.6)	1.00 (ref)	256 (46.4)	1.00 (ref)
Yes	3035 (64.0)	937 (73.3)	1.44 (1.22‐1.70)*	926 (71.4)	1.33 (1.13‐1.56)*	296 (53.6)	0.69 (0.55‐0.86)*
Tumor stage
Stage 0‐IIA	2246 (65.9)	580 (59.1)	1.00 (ref)	591 (61.3)	1.00 (ref)	238 (63.8)	1.00 (ref)
Stage IIB‐IV	1163 (34.1)	402 (40.9)	1.28 (0.95‐1.71)	373 (38.7)	1.22 (0.90‐1.64)	135 (36.2)	1.06 (0.66‐1.69)
Tumor size (cm)
≤2	2221 (50.7)	509 (42.5)	1.00 (ref)	521 (43.5)	1.00 (ref)	185 (38.9)	1.00 (ref)
>2	2158 (49.3)	690 (57.5)	1.19 (0.99‐1.42)	676 (56.5)	1.28 (1.07‐1.53)*	291 (61.1)	1.65 (1.27‐2.15)*
Lymph node metastasis
No	1865 (51.2)	493 (47.3)	1.00 (ref)	517 (50.6)	1.00 (ref)	213 (53.1)	1.00 (ref)
Yes	1781 (48.8)	549 (52.7)	0.92 (0.72‐1.19)	505 (49.4)	0.80 (0.62‐1.04)	188 (46.9)	0.72 (0.48‐1.09)

HER2, human epidermal growth factor receptor 2.

Statistically significant at P < 0.05.